FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLYXAMBI (empagliflozin and linagliptin)

Snippet

SUPPL AP for GLYXAMBI (EMPAGLIFLOZIN AND LINAGLIPTIN)